DGRW offers exposure, albeit modest, to another stock excluded by dividend increase streak ETFs that has already shown a penchant for payout growth although it is a relatively new dividend payer. DGRW has a 10.6% weight to health care stocks, including a 1.2% weight to Amgen (NasdaqGS: AMGN).
In the third quarter of 2011, Amgen paid its first cash dividend. The payout has since more than doubled while the stock has nearly tripled. Because it does not weight by dividend increase streak or yield, DGRW has the flexibility to include Amgen, just it could eventually include Gilead Sciences (NasdaqGS: GILD), which announced a new dividend of $1.72 per share per year Tuesday. [Gilead Could Goose Biotech ETFs]
WisdomTree U.S. Dividend Growth Fund
Tom Lydon’s clients own shares of Apple. Todd Shriber owns shares of DGRW.